Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H38F6O3 |
Molecular Weight | 524.5792 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](CCCC(O)(C(F)(F)F)C(F)(F)F)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C
InChI
InChIKey=XPYGGHVSFMUHLH-UUSULHAXSA-N
InChI=1S/C27H38F6O3/c1-16(6-4-13-25(36,26(28,29)30)27(31,32)33)21-10-11-22-18(7-5-12-24(21,22)3)8-9-19-14-20(34)15-23(35)17(19)2/h8-9,16,20-23,34-36H,2,4-7,10-15H2,1,3H3/b18-8+,19-9-/t16-,20-,21-,22+,23+,24-/m1/s1
Molecular Formula | C27H38F6O3 |
Molecular Weight | 524.5792 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 2 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://en.pharmacodia.com/yaodu/html/v1/chemicals/92cc227532d17e56e07902b254dfad10.htmlCurator's Comment: description was created based on several sources, including
http://link.springer.com/article/10.1007/s007740050027
http://www.ncbi.nlm.nih.gov/pubmed/15632470
Sources: http://en.pharmacodia.com/yaodu/html/v1/chemicals/92cc227532d17e56e07902b254dfad10.html
Curator's Comment: description was created based on several sources, including
http://link.springer.com/article/10.1007/s007740050027
http://www.ncbi.nlm.nih.gov/pubmed/15632470
Falecalcitriol is an analog of calcitriol. Falecalcitriol was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on Apr 4, 2001. It was co-developed by Taisho, Dainippon Sumitomo and Kissei, then marketed as Hornel by Taisho and Taisho Toyama or as Fulstan by Dainippon Sumitomo Pharma and Kissei in JP. It has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo. This medicine improves bone disease and symptoms caused by shortage of vitamin D, etc. It also prompts calcium absorption to supply lacked calcium and prevents bone-thinning. It is usually used to treat secondary hyperparathyroidism under maintenance dialysis, hypoparathyroidism, rickets or osteomalacia. Falecalcitriol regulates the proliferation of parathyroid cells and parathyroid hormone synthesis possibly via binding to a nuclear receptor for vitamin D (VDR). It is often not possible to administer doses high enough to sufficiently inhibit parathyroid hormones because of the risk of hypercalcemia and hyperphosphatemia.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
28 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8155746/ |
2 μg single, oral dose: 2 μg route of administration: Oral experiment type: SINGLE co-administered: |
FALECALCITRIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8155746/ |
2 μg single, oral dose: 2 μg route of administration: Oral experiment type: SINGLE co-administered: |
FALECALCITRIOL serum | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.3 ug 1 times / day multiple, oral Studied dose Dose: 0.3 ug, 1 times / day Route: oral Route: multiple Dose: 0.3 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: FED Sources: |
Other AEs: Hypercalcemia, anorexia... Other AEs: Hypercalcemia (9 patients) Sources: anorexia (1 pt) |
2 ug single, oral Studied dose |
healthy Health Status: healthy Sex: unknown Food Status: UNKNOWN Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
anorexia | 1 pt | 0.3 ug 1 times / day multiple, oral Studied dose Dose: 0.3 ug, 1 times / day Route: oral Route: multiple Dose: 0.3 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: FED Sources: |
Hypercalcemia | 9 patients | 0.3 ug 1 times / day multiple, oral Studied dose Dose: 0.3 ug, 1 times / day Route: oral Route: multiple Dose: 0.3 ug, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sex: M+F Food Status: FED Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D3. | 2000 Aug |
|
Enhanced coactivator binding and transcriptional activation of mutant vitamin D receptors from patients with hereditary 1,25-dihydroxyvitamin D-resistant rickets by phosphorylation and vitamin D analogs. | 2005 Sep |
Patents
Sample Use Guides
The recommended dose is 0.3 μg once daily for secondary hyperparathyroidism and 0.3-0.9 μg once daily for hypoparathyroidism, rickets or osteomalacia.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/10821342
1,25(OH)2 D3 decreased the expression of ERbeta proteins in smooth muscle cells and increased the ERalpha isoform in E304 cells by 40% to 75%
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:39 GMT 2025
by
admin
on
Mon Mar 31 18:05:39 GMT 2025
|
Record UNII |
G70A8514T8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C39713
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7103
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
DTXSID601027560
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
SUB07498MIG
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
5282190
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
1127
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
C040488
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106158
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
100000081532
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
83805-11-2
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
G70A8514T8
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
C80884
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY | |||
|
FALECALCITRIOL
Created by
admin on Mon Mar 31 18:05:39 GMT 2025 , Edited by admin on Mon Mar 31 18:05:39 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
TARGET -> AGONIST |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|